Clinical Trial Update: EPO906 Therapy in Patients With Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of EPO906 therapy in advanced melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• EPO906

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 2 | Status: COMPLETED